Krsnaa Diagnostics Ltd provides a range of technology-enabled diagnostic services such as imaging, clinical laboratory, and teleradiology services to hospitals, medical colleges, and community health centers across India with an extensive network across non-metro and lower-tier cities and towns.
Q2 FY26 Earnings Results for NSE: KRSNAA (Krsnaa Diagnostics Limited)
-
Revenue from Operations: ₹183 crore, up 2.2% YoY from ₹179 crore in Q2 FY25
-
EBITDA: ₹59.24 crore, up 19.9% YoY; EBITDA margin expanded by 222 bps to 28.74%
-
Profit After Tax (PAT): ₹23 crore, up 4.5% YoY from ₹22 crore
-
Net profit margin approximately 11.6%
-
Total assets stood at ₹1506.69 crore; total equity at ₹922.95 crore
-
Cash and cash equivalents: ₹10.56 crore
-
Operating cash flow for H1 FY26: ₹51.87 crore
-
Consistent growth in domestic and international markets with steady margin improvement
Management Commentary & Strategic Insights
-
Management highlighted the company’s strong operational performance despite market volatility
-
Expansion in diagnostic services supported by technology upgrades and increasing geographic reach
-
Focus on maintaining cost efficiency, enhancing service capability, and expanding product offerings
-
Long-term outlook remains positive with continued investments planned in diagnostic infrastructure
Q1 FY26 Earnings Results
-
Revenue from Operations: ₹186.08 crore, up 13.36% YoY
-
EBITDA: ₹25.63 crore, up 2.6% YoY; margin improving
-
PAT: ₹20.52 crore, up 14.5% YoY
-
Profit margin improvements attributed to efficiency gains and cost control
-
Management emphasized sustained growth momentum and footprint expansion efforts
To view the company’s previous earnings and latest concall transcripts, click here to visit the Alphastreet India news channel.